

12 August 2026

Control Bionics Accelerates Global Scaling with NeuroStrip App Launch on Apple and Microsoft Stores

Control Bionics Limited (ASX: CBL) today announced the NeuroStrip app is now available via Apple's App Store, the Mac App Store and the Microsoft Store, making the Company's wearable surface electromyography (sEMG) platform more accessible on commonly used devices.

The free-to-download app enables clinicians, physiotherapists, researchers and sporting organisations to connect to and use the NeuroStrip platform through their existing compatible devices, without requiring custom software installation.

NeuroStrip is the Company's proprietary wearable sEMG sensor platform, designed for use in elite sports performance, clinical rehabilitation and research settings. NeuroStrip hardware is supplied in markets where the Company holds the applicable regulatory registrations.

Control Bionics CEO and Managing Director Jeremy Steele said: "Making NeuroStrip available through major app stores removes friction for customers and provides a more scalable way to distribute and support the platform globally. It expands access to our technology and supports our strategy to grow recurring software and subscription revenue."

"Our customers can now find and use our software the same way they access everything else on their devices. It opens the platform to a far wider audience than we could reach through direct distribution alone," he said.

The app launch builds on growing customer engagement across Australia, New Zealand, the United States, Europe and Japan. NeuroStrip is subject to US FDA establishment registration and device listing. Regulatory applications are progressing in Australia and the European Union.

This announcement has been authorised for release to the ASX by the CEO of Control Bionics Limited.

For further information, please contact:

Jeremy Steele
CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley
Company Secretary
brettcrowley@controlbionics.com

About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, and converts them into measurable, decision-ready outcomes across four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. Control Bionics' technology does not require surgery or implantation. Its NeuroNode system holds regulatory clearances in the US, Australia and Europe; NeuroStrip holds US FDA establishment registration and device listing, with further registrations in progress. The Company is a registered NDIS provider in Australia.

Apple and Mac are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Microsoft and Microsoft Store are trademarks of the Microsoft group of companies. This announcement may contain forward-looking statements, which are based on current expectations and assumptions and are subject to risks and uncertainties; actual results may differ materially. The Company does not undertake to update forward-looking statements except as required by law.

